Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Smith-Magenis Syndrome × Melatonin × Clear all

Phase

Phase 3 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Tuberous Sclerosis 1 Smith-Magenis Syndrome 1 Relapsed Malignant Solid Tumor 1 Parasomnias 1 Breast Neoplasms 1 Autism Spectrum Disorder 1 Angelman Syndrome 1

Interventions

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01903681 2014-04-04

Assessment of the Pharmacokinetics of Circadin® in Children With Neurodevelopmental Disorders and Sleep Disturbances

Neurim Pharmaceuticals Ltd.

Phase 1 Completed

Autism Spectrum Disorder, Tuberous Sclerosis, Angelman Syndrome, Parasomnias, Smith-Magenis Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon ⚡